Precision Diagnosis and Prospective Cohort study for Myasthenia Gravis

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000037676

Enrollment

Unknown

Registered

2020-08-30

Start date

2020-10-01

Completion date

Unknown

Last updated

2020-11-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myasthenia Gravis

Interventions

case series:Nil

Eligibility

Sex/Gender

All

Age

1 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. Fluctuating muscle weakness and fatigability, along with one of the below: 2. more than 10% amplitude decrement in low frequency repetitive nerve stimulation,less than 10% amplitude increment in high frequency repetitive nerve stimulation; 3. anti-AChR or MuSK antibody positivity; 4. positive to the neostigmine test; 5. understanding and assigning the informed consent form, and having a good compliance with the follow up

Exclusion criteria

Exclusion criteria: 1. Excluding the possible diagnosis of Lambert-Eaton syndrome, congenital myasthenia syndrome,botulism injection, chronic progressive extraocular ophthalmoplegia, etc; 2. participating other clinical trials; 3. poor compliance to the follow up.

Design outcomes

Primary

Measure	Time frame
MGFA post intervension status;	—

Secondary

Measure	Time frame
Quatitative Myasthenia Gravis scores;Manual Muscle Testing scores;	—

Countries

China

Contacts

Public ContactChongbo Zhao

Huashan Hospital, Fudan University

zhao_chongbo@fudan.edu.cn+86 21-52889999

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026